Keros Therapeutics Inc (KROS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $202.13M
Last updated: Nov 17, 2026 at 11:05 AM ET
Keros Therapeutics Inc (KROS) Stock Forecast
Analysts expect Keros Therapeutics (KROS) to earn -$3.35 per share in the fiscal year ending Dec 31, 2026, on revenue of $41.25M. Of 7 analysts, 4 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 2.43, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 57% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 4 | 57.1% |
| Hold | 3 | 42.9% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 66.7%.
- Fiscal year ending Dec 31, 2026
- -$3.35
- EPS consensus, revenue $41.25M
- Fiscal year ending Dec 31, 2027
- -$5.96
- EPS consensus, revenue $13.73M
- Next report
- Mar 2, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.35 | -$3.35 to -$3.35 | 1 | $41.25M | $40.38M to $43.00M | 3 |
| Dec 31, 2027 | -$5.96 | -$7.07 to -$3.84 | 4 | $13.73M | N/A | 7 |
Quarterly Estimates
The EPS consensus rises from -$1.69 for the quarter ending Dec 31, 2026 to -$1.51 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.69 | -$2.43 to -$1.46 | 9 | $437141 | N/A | 9 |
| Mar 31, 2027 | -$1.51 | -$1.51 to -$1.51 | 1 | N/A | N/A | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 8 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 6 |
| Quarter ending Mar 31, 2027 | 0 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$5.11.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.35 | -$5.22 | -$5.22 | -$5.22 | -$5.11 | N/A |
| Fiscal year ending Dec 31, 2027 | -$5.96 | -$6.62 | -$6.62 | -$6.62 | -$6.38 | N/A |
| Quarter ending Mar 31, 2027 | -$1.51 | -$2.10 | -$2.10 | -$2.10 | -$1.83 | N/A |
Frequently Asked Questions About KROS
What is the KROS stock forecast?
Consensus analyst estimates put Keros Therapeutics's EPS at -$3.35 for the fiscal year ending Dec 31, 2026, on revenue of $41.25M. The consensus rating from 7 analysts is Buy.
How do analysts rate KROS stock?
Of 7 analysts covering Keros Therapeutics, 0 rate it Strong Buy, 4 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from KROS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.35, with estimates from -$3.35 to -$3.35 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$5.96, with estimates from -$7.07 to -$3.84 from 4 analysts.
What revenue do analysts expect from Keros Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $41.25M, with estimates from $40.38M to $43.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $13.73M.
How many analysts cover KROS?
7 analysts rate Keros Therapeutics stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
KROS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors